Parters Vii L Pblair James ... Net Worth

The estimated Net Worth of Parters Vii L Pblair James ... is at least $16.6 Million dollars as of 4 June 2013. Parters James owns over 159,192 units of Clovis Oncology Inc stock worth over $206,540 and over the last 12 years Parters sold CLVS stock worth over $16,428,119.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Parters James CLVS stock SEC Form 4 insiders trading

Parters has made over 2 trades of the Clovis Oncology Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently Parters sold 159,192 units of CLVS stock worth $10,280,619 on 4 June 2013.

The largest trade Parters's ever made was selling 250,000 units of Clovis Oncology Inc stock on 4 March 2013 worth over $6,147,500. On average, Parters trades about 204,596 units every 46 days since 2013. As of 4 June 2013 Parters still owns at least 2,581,745 units of Clovis Oncology Inc stock.

You can see the complete history of Parters James stock trades at the bottom of the page.

Insiders trading at Clovis Oncology Inc

Over the last 13 years, insiders at Clovis Oncology Inc have traded over $37,405,827 worth of Clovis Oncology Inc stock and bought 24,337,722 units worth $298,497,645 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Peter J Barris. On average, Clovis Oncology Inc executives and independent directors trade stock every 17 days with the average trade being worth of $8,863. The most recent stock trade was executed by Paul Edward Gross on 1 November 2022, trading 10,248 units of CLVS stock currently worth $820.

What does Clovis Oncology Inc do?

Complete history of Parters James stock trades at Clovis Oncology Inc

Clovis Oncology Inc executives and stock owners

Clovis Oncology Inc executives and other stock owners filed with the SEC include:

• Patrick J. Mahaffy,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. Lindsey Rolfe B.Sc., BSc, MB ChB, MRCP, FFPM,
  Exec. VP of Clinical Devel. & Pharmacovigilance and Chief Medical Officer
• Patrick J. Mahaffy MA,
  Co-Founder, CEO, Pres & Exec. Director
• Dr. Gillian C. Ivers-Read,
  Co-Founder, Chief Regulatory Officer & Exec. VP of Technical Operations
• Paul Edward Gross,
  Exec. VP, Gen. Counsel & Sec.
• Daniel W. Muehl,
  Exec. VP & CFO
• Dr. Gillian C. Ivers-Read BSc,
  Co-Founder, Exec. VP & Chief Regulatory Officer
• Anna Sussman,
  VP of Investor Relations
• Ann Bozeman,
  Exec. VP of HR
• Breanna Burkart,
  VP of Investor Relations & Corp. Communications
• Dr. Thomas Fuglsang Harding B.Sc., Ph.D.,
  Exec. VP & Chief Scientific Officer
• Keith T. Flaherty,
  Director
• Daniel W Muehl,
  See Remarks
• Lindsey Rolfe,
  See Remarks
• Thorlef Spickschen,
  Director
• Paul H Klingenstein,
  Director
• M James Barrett,
  Director
• Gillian C Ivers Read,
  See Remarks
• Ginger L Graham,
  Director
• Corwin Dale Hooks,
  See Remarks
• Edward J Mc Kinley,
  Director
• Brian G Atwood,
  Director
• Patrick J Mahaffy,
  See Remarks
• Richard A. Fair,
  Director
• Robert Azelby,
  Director
• Paul Edward Gross,
  See Remarks
• Erle T Mast,
  Executive VP and CFO
• Enterprise Associates 13 Lp...,
  
• Harry R Weller,
  10% owner
• John C Reed,
  Director
• Patrick J Kerins,
  10% owner
• Kathleen K Schoemaker,
  10% owner
• C Richard Kramlich,
  10% owner
• Parters Vii L Pblair James ...,
  
• Peter J Barris,
  10% owner
• Brian H Dovey,
  10% owner
• Steven L. Hoerter,
  SEE REMARKS
• Jesse I Treu,
  10% owner
• Ravi Viswanathan,
  10% owner
• Partners 13, Limited Partne...,
  
• Vii Associates Lp Dp,
  10% owner
• Venture Capital Iv, L.P.Ver...,
  
• David M Mott,
  10% owner
• Scott D Sandell,
  10% owner
• Brian K Halak,
  10% owner
• Nicole Vitullo,
  10% owner
• Vii Associates Lpblair Jame...,
  
• Krishna Kittu Kolluri,
  10% owner
• Ryan D Drant,
  10% owner
• Parters Vii L P Domain,
  10% owner
• Forest Baskett,
  10% owner
• Enterprise Associates 13 Lp...,
  10% owner
• James C Blair,
  Director
• Thomas C. Harding,
  See Remarks